News
Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?
Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by pegylation, which results in an approximately 1.5× prolonged biological half-life compared to standard half-life FVIII. Previous studies have already confirmed the favorable profile of this drug in prophylaxis for patients with hemophilia A. Recently published results of a prospective multicenter continuation study in children and adult patients under 75 years old with severe hemophilia A (baseline FVIII level < 1%) were based on an observation period…
Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the…
Anxiety Disorders and Autoimmune Thyroiditis – A Connection Rather Than Coincidence?
Anxiolytics commonly target the central nervous system. Newly published research by Ukrainian…
Targeted Treatment and Quality of Life in Patients with Follicular Lymphoma
The GALLIUM clinical trial evaluated chemotherapy in combination with targeted treatment using…
Sport Therapy as Part of Hemophilia Management
A study by authors from the University of Wuppertal in Germany specifically examined the impact of…
EHL preparations have the potential to change the quality of life for people with hemophilia
Within the therapeutic modalities for hemophilia, the current era offers a number of preparations.…
Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection
To date, 45 cases of idiopathic (autoimmune) thrombocytopenic purpura (ITP) in individuals with…
Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis
Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it…
Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the…
Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory…